Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 271 AL 285

Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer's Disease

Zeng F, Li Y, Xu Y, Yang J, Liu Z, Li X, Ren L.

Curr Alzheimer Res. 2019;16(12):1132-1142. doi: 10.2174/1567205016666191031163504.

Extracellular vesicles as an emerging tool for the early detection of Alzheimer's disease

Li TR, Wang XN, Sheng C, Li YX, Li FZ, Sun Y, Han Y.

Mech Ageing Dev. 2019 Dec;184:111175. doi: 10.1016/j.mad.2019.111175. Epub 2019 Nov 1.

Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease

Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, Marek K, Gray M, Hefti F.

J Prev Alzheimers Dis. 2019;6(4):228-231. doi: 10.14283/jpad.2019.37.

Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease

Jia J, Ji Y, Feng T, Ye Q, Peng D, Kuang W, Ning Y, Liang Z, Fan D, Wei W, Li Y, Xiao S.

J Alzheimers Dis. 2019;72(4):1313-1322. doi: 10.3233/JAD-190791.

Madelung's Disease Leading to Presenile Dementia in a Non-alcoholic Patient

El Hasbani G, Assaker R, Nithisoontorn S, Plath W, Lopez EO, Gamarra JV, Kofahi A, Bertely C, Dimitrov V.

Med Arch. 2019 Aug;73(4):285-287. doi: 10.5455/medarh.2019.73.285-287.

Cognitive symptoms of Alzheimer's disease: clinical management and prevention

Joe E, Ringman JM.

BMJ. 2019 Dec 6;367:l6217. doi: 10.1136/bmj.l6217.

Arterial Spin Labeling Magnetic Resonance Imaging in the Assessment of Non-Convulsive Status Epilepticus in Alzheimer's Disease: A Report of Two Cases

Mutoh T, Eguchi K, Yamamoto S, Yasui N, Taki Y.

Am J Case Rep. 2019 Dec 16;20:1883-1887. doi: 10.12659/AJCR.919938.

Current and Emerging Solutions to Challenges in the Management of Alzheimer's Disease

Atri A, Goldfarb D, Sheard S, Shaughnessy L.

J Clin Psychiatry. 2019 Dec 3;80(6):MS18002AH3C. doi: 10.4088/JCP.MS18002AH3C.

Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases

Páez JA, Campillo NE.

Curr Med Chem. 2019;26(18):3300-3340. doi: 10.2174/0929867325666180226095132.

Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research

Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Vergallo A, Farlow MR, Snyder PJ, Giacobini E, Khachaturian ZS.

J Prev Alzheimers Dis. 2019;6(1):2-15. doi: 10.14283/jpad.2018.43.

The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease

Rubin LH, Sundermann EE, Moore DJ.

J Neurovirol. 2019 Oct;25(5):661-672. doi: 10.1007/s13365-018-0702-9. Epub 2019 Jan 22.

PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism

Altinoz MA, Ozpinar A.

Int Immunopharmacol. 2019 Apr;69:245-256. doi: 10.1016/j.intimp.2019.01.057. Epub 2019 Feb 8.

Auditory Brainstem Dysfunction, Non-Invasive Biomarkers for Early Diagnosis and Monitoring of Alzheimer's Disease in Young Urban Residents Exposed to Air Pollution

Mansour Y, Blackburn K, González-González LO, Calderón-Garcidueñas L, Kulesza RJ.

J Alzheimers Dis. 2019;67(4):1147-1155. doi: 10.3233/JAD-181186.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias